ENDRA Life Sciences Inc. (ENDRA) entered into a definitive merger agreement with Noble Africa LLC (Noble), a subsidiary of ASP Isotopes Inc. (ASPI). The transaction includes a $50 million private placement (Noble Investment) of Class A and Class B units at $6.57 per unit, closing immediately prior to the merger. ASPI will contribute its equity interest in Renergen Limited to Noble in exchange for 55,500,000 Class B units, which will carry 10 votes per share. Upon closing, ENDRA will be renamed Noble Africa Inc. and will have a dual-class common stock structure. The combined company's board will consist of seven directors: one CEO director, five designated by Noble, and one designated by ENDRA. The merger is subject to ENDRA stockholder approval, Nasdaq listing requirements, and other customary closing conditions. The transaction is expected to close by December 31, 2026.